I
24.59
-0.60 (-2.38%)
| Previous Close | 25.19 |
| Open | 25.46 |
| Volume | 232,316 |
| Avg. Volume (3M) | 2,864,200 |
| Market Cap | 3,068,090,112 |
| Price / Earnings (TTM) | 30.36 |
| Price / Earnings (Forward) | 12.30 |
| Price / Sales | 2.69 |
| Price / Book | 145.25 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -5.30% |
| Operating Margin (TTM) | 25.56% |
| Diluted EPS (TTM) | -0.050 |
| Quarterly Revenue Growth (YOY) | -6.30% |
| Quarterly Earnings Growth (YOY) | -23.00% |
| Current Ratio (MRQ) | 0.880 |
| Operating Cash Flow (TTM) | 135.00 M |
| Levered Free Cash Flow (TTM) | 264.88 M |
| Return on Assets (TTM) | 12.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Bullish | |
| Stock | Indivior PLC | Bullish | Bullish |
AIStockmoo Score
1.6
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 4.02% |
| % Held by Institutions | 89.09% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Madison Avenue Partners, Lp | 30 Jun 2025 | 7,922,178 |
| Newtyn Management, Llc | 30 Jun 2025 | 2,607,018 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 34.00 (Craig-Hallum, 38.27%) | Buy |
| Median | 28.00 (13.87%) | |
| Low | 20.00 (Jefferies, -18.67%) | Buy |
| Average | 27.33 (11.14%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 20.85 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 27 Aug 2025 | 34.00 (38.27%) | Buy | 24.36 |
| HC Wainwright & Co. | 06 Aug 2025 | 28.00 (13.87%) | Buy | 22.00 |
| Jefferies | 22 Jul 2025 | 20.00 (-18.67%) | Buy | 16.18 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 Oct 2025 | Announcement | Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment |
| 01 Oct 2025 | Announcement | Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation |
| 20 Aug 2025 | Announcement | Indivior to Participate in Upcoming Investor Events |
| 31 Jul 2025 | Announcement | Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance |
| 25 Jul 2025 | Announcement | Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained |
| 23 Jul 2025 | Announcement | Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |